Recurrent primary focal segmental glomerulosclerosis managed with intensified plasma exchange and concomitant monitoring of soluble urokinase-type plasminogen activator receptor-mediated podocyte β3-integrin activation

Transplantation

Volumn 99, Issue 12, 2015, Pages 2593-2597

  Staeck, Oliver ^a   Slowinski, Torsten ^a   Lieker, Ina ^a   Wu, Kaiyin ^a   Rudolph, Birgit ^a   Schmidt, Danilo ^a   Brakemeier, Susanne ^a   Neumayer, Hans Hellmut ^a   Wei, Changli ^b   Reiser, Jochen ^b   Budde, Klemens ^a   Halleck, Fabian ^a   Khadzhynov, Dmytro ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; UROKINASE RECEPTOR;

ADULT; ARTICLE; CELLULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; GRAFT FAILURE; HISTOPATHOLOGY; HUMAN; KIDNEY TRANSPLANTATION; MALE; PATIENT MONITORING; PLASMAPHERESIS; PODOCYTE; PODOCYTE BETA3 INTEGRIN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REBOUND; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; FOLLOW UP; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; METABOLISM; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; RETROSPECTIVE STUDY;

ADULT; FEMALE; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INTEGRIN BETA3; MALE; MONITORING, PHYSIOLOGIC; PLASMA EXCHANGE; PODOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84952630132     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000914     Document Type: Article

References (32)

1. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004; 44: 815-825.
2. Chun MJ, Korbet SM, Schwartz MM, et al. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004; 15: 2169-2177.
3. Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005; 16: 1061-1068.
4. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol. 1992; 2(12 Suppl): S258-S263.
5. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl JMed. 1996; 334: 878-883.
6. Artero ML, Sharma R, Savin VJ, et al. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994; 23: 574-581.
7. ThunøM, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009; 27: 157-172.
8. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17: 952-960.
9. Huang J, Liu G, Zhang YM, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014; 12: 81.
10. Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013; 96: 649-656.
11. Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012; 23: 2051-2059.
12. Deegens JK, Andresdottir MB, Croockewit S, et al. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int. 2004; 17: 151-157.
13. Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014; 6: 256ra136.
14. Laufer J, Ettenger RB, Ho WG, et al. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation. 1988; 46: 540-542.
15. Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant. 2013; 13: 266-274.
16. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005; 5: 1179-1185.
17. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl JMed. 1994; 330: 7-14.
18. Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant. 2004; 19: 1036-1040.
19. Straatmann C, Kallash M, KillackeyM, et al. Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant. 2014; 18: 29-34.
20. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80: 868-878.
21. Westhoff TH, Schmidt S, ZidekW, et al. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol. 2006; 65: 393-400.
22. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol. 2014; 39: 322-330.
23. Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009; 9: 1081-1086.
24. Sprenger KB, Huber K, Kratz W, et al. Nomograms for the prediction of patient's plasma volume in plasma exchange therapy from height, weight, and hematocrit. J Clin Apher. 1987; 3: 185-190.
25. Honda S, Tomiyama Y, Pelletier AJ, et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem. 1995; 270: 11947-11954.
26. Schlöndorff D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int. 2014; 85: 499-501.
27. Morath C, Wei C, Macher-Goeppinger S, et al. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther. 2013; 20: 226-229.
28. Harita Y, Ishizuka K, Tanego A, et al. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol. 2014; 29: 1553-1560.
29. Meijers B, Maas RJ, Sprangers B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014; 85: 636-640.
30. Wada T, Nangaku M, Maruyama S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 2014; 85: 641-648.
31. Reiser J, Chapman H. Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken. J Am Soc Nephrol. 2014; 25: 1611-1613.
32. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012; 16: R149.